Dosimetric Analyses of Patients with Metastatic Gastrointestinal Neuroendocrine Tumors Treated with PRCRT Using 177 Lu-DOTATATE with Capecitabine as Radiosensitizer
#1817
Introduction: Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE is gaining acceptance as safe and effective therapy for inoperable neuroendocrine tumors (NET). A radiosensitizing chemotherapeutic drug -capecitabine, the prodrug of 5-Flourouracil, is included in the protocol to further enhance therapeutic efficacy.
Aim(s): To assess the biodistribution and present reasonable estimates of normal organ doses to liver, spleen and kidneys using 177 Lu-DOTATATE and Capecitabine.
Materials and methods: Fifteen patients (mean age 51.4y) of metastatic gastric-intestinal NETs diagnosed with 68Ga-DOTANOC PET-CT,histopathology and biochemical markers were were prescribed oral tablet capecitabine in dose of 500mg/m2 twice daily for 14 days, commencing 9 days prior to PRRT. 6.66 to 7.4 GBq (180-200 mCi) of 177Lu-DOTATATE was infused to each patient with co-infusion of amino acid solution for renal protection. Each patient underwent whole-body scans at 2, 24 and 96 hours post therapy. The organs included in dosimetry were kidney, liver, spleen and tumor sites. All calculations were done using HERMES software
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Dureja S
Authors: Dureja S, Thakral P, Pant V, Pallavi U, Vindhya M,
Keywords: PRRT, radiosensitizer,
To read the full abstract, please log into your ENETS Member account.